Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids

Jaron Rabinovici, Matthias David, Hidenobu Fukunishi, Yutaka Morita, Bobbie S. Gostout, Elizabeth A Stewart

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

Objective: To report all pregnancies to date after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the conservative treatment of clinically significant uterine fibroids. Design: Prospective registry of all known pregnancies occurring after MRgFUS maintained by the device manufacturer and reported to the Food and Drug Administration. Setting: World experience of pregnancies after treatment with reports from 13 sites in seven countries. Patient(s): Fifty-one reproductive-age women with uterine leiomyomas. Intervention(s): Women underwent MRgFUS treatment for symptomatic uterine leiomyomas before this report. Main Outcome Measure(s): Pregnancy outcomes and complications. Result(s): Fifty-four pregnancies in 51 women have occurred after MRgFUS treatment of uterine leiomyomas. The mean time to conception was 8 months after treatment. Live births occurred in 41% of pregnancies, with a 28% spontaneous abortion rate, an 11% rate of elective pregnancy termination, and 11 (20%) ongoing pregnancies beyond 20 gestational weeks. The mean birth weight was 3.3 kg, and the vaginal delivery rate was 64%. Conclusion(s): Preliminary pregnancy experience after MRgFUS is encouraging, with a high rate of delivered and ongoing pregnancies.

Original languageEnglish (US)
Pages (from-to)199-209
Number of pages11
JournalFertility and Sterility
Volume93
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Leiomyoma
Pregnancy Outcome
Magnetic Resonance Spectroscopy
Pregnancy
Pregnancy Complications
Conservative Treatment
Induced Abortion
Live Birth
Spontaneous Abortion
Pregnancy Rate
United States Food and Drug Administration
Therapeutics
Birth Weight
Registries
Outcome Assessment (Health Care)
Equipment and Supplies

Keywords

  • fibroid
  • leiomyoma
  • myomectomy
  • pregnancy
  • ultrasound
  • Uterus

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. / Rabinovici, Jaron; David, Matthias; Fukunishi, Hidenobu; Morita, Yutaka; Gostout, Bobbie S.; Stewart, Elizabeth A.

In: Fertility and Sterility, Vol. 93, No. 1, 01.01.2010, p. 199-209.

Research output: Contribution to journalArticle

Rabinovici, Jaron ; David, Matthias ; Fukunishi, Hidenobu ; Morita, Yutaka ; Gostout, Bobbie S. ; Stewart, Elizabeth A. / Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. In: Fertility and Sterility. 2010 ; Vol. 93, No. 1. pp. 199-209.
@article{3e3f30e146dc477cb80847092ad22046,
title = "Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids",
abstract = "Objective: To report all pregnancies to date after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the conservative treatment of clinically significant uterine fibroids. Design: Prospective registry of all known pregnancies occurring after MRgFUS maintained by the device manufacturer and reported to the Food and Drug Administration. Setting: World experience of pregnancies after treatment with reports from 13 sites in seven countries. Patient(s): Fifty-one reproductive-age women with uterine leiomyomas. Intervention(s): Women underwent MRgFUS treatment for symptomatic uterine leiomyomas before this report. Main Outcome Measure(s): Pregnancy outcomes and complications. Result(s): Fifty-four pregnancies in 51 women have occurred after MRgFUS treatment of uterine leiomyomas. The mean time to conception was 8 months after treatment. Live births occurred in 41{\%} of pregnancies, with a 28{\%} spontaneous abortion rate, an 11{\%} rate of elective pregnancy termination, and 11 (20{\%}) ongoing pregnancies beyond 20 gestational weeks. The mean birth weight was 3.3 kg, and the vaginal delivery rate was 64{\%}. Conclusion(s): Preliminary pregnancy experience after MRgFUS is encouraging, with a high rate of delivered and ongoing pregnancies.",
keywords = "fibroid, leiomyoma, myomectomy, pregnancy, ultrasound, Uterus",
author = "Jaron Rabinovici and Matthias David and Hidenobu Fukunishi and Yutaka Morita and Gostout, {Bobbie S.} and Stewart, {Elizabeth A}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.fertnstert.2008.10.001",
language = "English (US)",
volume = "93",
pages = "199--209",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids

AU - Rabinovici, Jaron

AU - David, Matthias

AU - Fukunishi, Hidenobu

AU - Morita, Yutaka

AU - Gostout, Bobbie S.

AU - Stewart, Elizabeth A

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Objective: To report all pregnancies to date after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the conservative treatment of clinically significant uterine fibroids. Design: Prospective registry of all known pregnancies occurring after MRgFUS maintained by the device manufacturer and reported to the Food and Drug Administration. Setting: World experience of pregnancies after treatment with reports from 13 sites in seven countries. Patient(s): Fifty-one reproductive-age women with uterine leiomyomas. Intervention(s): Women underwent MRgFUS treatment for symptomatic uterine leiomyomas before this report. Main Outcome Measure(s): Pregnancy outcomes and complications. Result(s): Fifty-four pregnancies in 51 women have occurred after MRgFUS treatment of uterine leiomyomas. The mean time to conception was 8 months after treatment. Live births occurred in 41% of pregnancies, with a 28% spontaneous abortion rate, an 11% rate of elective pregnancy termination, and 11 (20%) ongoing pregnancies beyond 20 gestational weeks. The mean birth weight was 3.3 kg, and the vaginal delivery rate was 64%. Conclusion(s): Preliminary pregnancy experience after MRgFUS is encouraging, with a high rate of delivered and ongoing pregnancies.

AB - Objective: To report all pregnancies to date after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the conservative treatment of clinically significant uterine fibroids. Design: Prospective registry of all known pregnancies occurring after MRgFUS maintained by the device manufacturer and reported to the Food and Drug Administration. Setting: World experience of pregnancies after treatment with reports from 13 sites in seven countries. Patient(s): Fifty-one reproductive-age women with uterine leiomyomas. Intervention(s): Women underwent MRgFUS treatment for symptomatic uterine leiomyomas before this report. Main Outcome Measure(s): Pregnancy outcomes and complications. Result(s): Fifty-four pregnancies in 51 women have occurred after MRgFUS treatment of uterine leiomyomas. The mean time to conception was 8 months after treatment. Live births occurred in 41% of pregnancies, with a 28% spontaneous abortion rate, an 11% rate of elective pregnancy termination, and 11 (20%) ongoing pregnancies beyond 20 gestational weeks. The mean birth weight was 3.3 kg, and the vaginal delivery rate was 64%. Conclusion(s): Preliminary pregnancy experience after MRgFUS is encouraging, with a high rate of delivered and ongoing pregnancies.

KW - fibroid

KW - leiomyoma

KW - myomectomy

KW - pregnancy

KW - ultrasound

KW - Uterus

UR - http://www.scopus.com/inward/record.url?scp=72749087284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72749087284&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2008.10.001

DO - 10.1016/j.fertnstert.2008.10.001

M3 - Article

C2 - 19013566

AN - SCOPUS:72749087284

VL - 93

SP - 199

EP - 209

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -